In vitro activities of BMS-207147 against over 600 contemporary clinical bloodstream isolates of Candida species from the SENTRY antimicrobial surveillance program in North America and Latin America

We compared the in vitro activity of BMS-207147, an investigational triazol e, with those of itraconazole and fluconazole against 613 clinical bloodstr eam isolates of Candida spp, collected from SENTRY participating hospitals during 1997 and 1998, Overall, BMS-207147 was the most active azole against all Candida spp, While both BMS-207147 and itraconazole displayed a stepwi se decrease in activity against isolates for which the fluconazole MICs wer e elevated, BMS-207147 had two- to fourfold greater activity than itraconaz ole both against Candida spp, that were dose-dependently fluconazole suscep tible and against those that were fluconazole resistant.